The right plan
For the right patient
Multiple myeloma (MM) survival rates can range from under 2 years to up to 20 years. Without knowing each patient's risk profile, it can be challenging to determine which treatment plan to start. MMprofilerTM with SKY92 helps to address this challenge.
Superior, data-driven decisions
MMprofilerTM with SKY92 is the only CE-IVD marked, prognostic risk-identification test that enables physicians to predict risk of MM progression more accurately, and:
helps physicians to more accurately identify high-risk patients in order to make more informed treatment decisions
is proven superior to currently-used biomarkers with greater accuracy in identifying high-risk patients
the MMprofilerTM with SKY92 gene signature risk classification results are independent from therapy choice, and function in the presence of any drug regimens (in clinical trials)